<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700791</url>
  </required_header>
  <id_info>
    <org_study_id>2008H0001</org_study_id>
    <nct_id>NCT00700791</nct_id>
  </id_info>
  <brief_title>Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars</brief_title>
  <official_title>Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chandan K Sen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to determine the efficacy of tocotrienol (TCT), a natural
      form of vitamin E, in preventing or reducing scar formation in human skin wounds as well as
      the basal levels of TCT in normal human skin and adipose tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scar formation is the physiological and inevitable end point of mammalian wound healing and
      there is substantial evidence that inflammation is an essential prerequisite for scarring.
      Although scar tissue restores the normal skin barrier, the new tissue is inferior in
      structural, aesthetic, and functional respects. The mammalian wound healing response may have
      originated during the time of high susceptibility to infection. Therefore, we may have
      developed speed optimized wound healing where a multiple redundant compensating rapid
      inflammatory response allows the wound to heal quickly without infection. The scar is then
      the price mammals have to pay for evolutionary survival after being wounded.

      Tocotrienol may be an effective tool to prevent or reduce normal, hypertrophic, or keloid
      scarring by mediating the inflammatory response. Tocotrienol is a safe and convenient
      treatment that could be used by mouth or topically. There has never been a study on the
      effectiveness of tocotrienol in preventing or reducing scar formation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.To determine the efficacy of TCT in improving the appearance of post-surgical scars following oral supplementation 2.To determine the efficacy of TCT in improving the appearance of post-surgical scars following topical application</measure>
    <time_frame>4 weeks prior to surgery and 12 weeks post surgery.</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Scar</condition>
  <arm_group>
    <arm_group_label>Group I Single Site Randomization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with 1 surgical scar will be given both oral placebo and topical cream placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II Single Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single surgical site will be given oral placebo and topical TCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III Single Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV Single Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I: Bilateral Site Randomization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II: Bilateral Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III: Bilateral Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV: Bilateral Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Skin and Adipost Tissue Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal human skin and adipose tissue will be collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Natural Vitamin E Tocotrienol supplement (TCT)</intervention_name>
    <description>Oral Vitamin E Tocotrienol Supplement (TCT)</description>
    <arm_group_label>Group III Single Site Randomization</arm_group_label>
    <arm_group_label>Group IV Single Site Randomization</arm_group_label>
    <arm_group_label>Group III: Bilateral Site Randomization</arm_group_label>
    <arm_group_label>Group IV: Bilateral Site Randomization</arm_group_label>
    <other_name>Oral TCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Natural Vitamin E Tocotrienol Cream (TCT)</intervention_name>
    <description>Natural Vitamin E Tocotrienol(TCT)Topical Cream</description>
    <arm_group_label>Group II Single Site Randomization</arm_group_label>
    <arm_group_label>Group IV Single Site Randomization</arm_group_label>
    <arm_group_label>Group II: Bilateral Site Randomization</arm_group_label>
    <arm_group_label>Group IV: Bilateral Site Randomization</arm_group_label>
    <other_name>Topical TCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Placebo</description>
    <arm_group_label>Group I Single Site Randomization</arm_group_label>
    <arm_group_label>Group II Single Site Randomization</arm_group_label>
    <arm_group_label>Group I: Bilateral Site Randomization</arm_group_label>
    <arm_group_label>Group II: Bilateral Site Randomization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <description>Topical Placebo Cream</description>
    <arm_group_label>Group I Single Site Randomization</arm_group_label>
    <arm_group_label>Group III Single Site Randomization</arm_group_label>
    <arm_group_label>Group I: Bilateral Site Randomization</arm_group_label>
    <arm_group_label>Group III: Bilateral Site Randomization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Non- smoker

          -  No current medications that alter liver metabolism (e.g., Phenobarbital, HmG co-A
             inhibitors, etc.)

          -  Non- pregnant or non-breastfeeding

          -  No current use of dietary supplements containing vitamin-E

          -  Not actively abusing drugs or alcohol

        Exclusion Criteria:

          -  Under 18 years of age

          -  Prisoners

          -  Current smoker

          -  Pregnant or breastfeeding

          -  HIV diagnosis

          -  Viral hepatitis diagnosis

          -  Immunosuppressive therapy

          -  Actively abusing drugs or alcohol

          -  Current use of dietary supplements containing vitamin-E
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandan K Sen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OSU Plastic Surgery - Knightsbridge</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Chandan K Sen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Single and bilateral body contouring surgical sites.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

